Frank Richard

Company: Heidelberg Pharma

Job title: Vice President - Medical

Bio:

Seminars:

Application of Dose Modification Strategies in HDP-101-01 FH Trial Guided Through Modelling & Simulation 9:30 am

A two-compartment model with linear clearance was applied to describe the PK of the total antibody PKPD modelling and simulation analyses confirmed that dose mitigation strategies reduced the impact of HDP-101 on thrombocytes by dose splitting or administering pre-medication with corticosteroids and antihistamines HDP-101 demonstrated an excellent safety profile up to 112.5 ug/kg/cycle dosing where…Read more

day: Conference Day One

Investigating the Effects on Modelling & Dosing When Expanding into ADC Combinations 9:30 am - 12:30 pm

Join this workshop to explore how next generation dosing strategies can unlock the full potential of ADC combination therapies. There is no silver bullet for treatment, and combinations are widely considered the next step in oncology treatment, so in this workshop you’ll dive into the latest thinking, tools, and translational tactics that are reshaping combination…Read more

day: Pre-Conference Workshop Day